-
Taletrectinib Displays Efficacy, Tolerability in ROS1+ NSCLC in Multiple Clinical Trials
17 Dec 2024 17:39 GMT
… .
During the 2024 International Association for the Study of Lung Cancer World Conference on Lung Cancer …
-
China NMPA approves Merck's Keytruda in combo with chemotherapy as neoadjuvant treatment, then continued as monotherapy after surgery as adjuvant treatment for patients with resectable stage II, IIIA or IIIB NSCLC
17 Dec 2024 10:55 GMT
… past president of the International Association for the Study of Lung Cancer (IASLC). “This approval represents …
-
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC
16 Dec 2024 11:52 GMT
… past president of the International Association for the Study of Lung Cancer (IASLC). “This approval represents …
-
International Association for the Study of Lung Cancer (IASLC) and Lung Cancer Research Foundation (LCRF) Announce Request for Proposals
12 Jan 2024 06:29 GMT
… , in partnership with the International Association for the Study of Lung Cancer, submissions are being accepted … ; Communications
ssullivan@lcrf.org
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (IASLC)
Chris Martin
IASLC …
-
Lung Cancer Research Foundation and the International Association for the Study of Lung Cancer (IASLC) Announce New Research Partnership
05 Dec 2023 15:01 GMT
… ; Communications
ssullivan@lcrf.org
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (IASLC)
Chris Martin
IASLC … -research-foundation-and-the-international-association-for-the-study-of-lung-cancer-iaslc-announce-new-research …
-
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
10 Dec 2024 13:00 GMT
… presentation at the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 Hot Topic …
-
US FDA grants breakthrough therapy designation to datopotamab deruxtecan for patients with previously treated advanced EGFR-mutated NSCLC
10 Dec 2024 05:11 GMT
… Cancer hosted by the International Association for the Study of Lung Cancer and simultaneously published in …
-
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
09 Dec 2024 12:13 GMT
… Cancer hosted by the International Association for the Study of Lung Cancer and simultaneously published in …
-
Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
09 Dec 2024 07:20 GMT
… Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC24) and simultaneously published …
-
Datopotamab deruxtecan demonstrated meaningful clinical activity in patients with previously treated advanced EGFR─mutated NSCLC in TROPION─Lung05 & TROPION─Lung01 pooled analysis
07 Dec 2024 11:09 GMT
…
Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC24) and simultaneously published …
About
© 1995-2024